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ABSTRACT
For the upfront adjuvant therapy of postmenopausal
estrogen receptor–positive breast cancer, the third-gen-
eration aromatase inhibitors (AIs) have shown a more
favourable overall risk–benefit profile than has tamox-
ifen. Benefits of the AIs include less frequent gyneco-
logic, cerebrovascular, and thromboembolic adverse
events; greater disease-free survival; and lower tumour
recurrence. Although approximately 25% of postmeno-
pausal women with early breast cancer report experi-
encing symptoms of arthralgia with AI therapy,
68-month data from the Arimidex, Tamoxifen, Alone
or in Combination trial showed that, compared with
tamoxifen, anastrozole treatment was associated with
only a modest increase in the incidence of joint symp-
toms. The events, which were mostly mild-to-moder-
ate in intensity, led to treatment withdrawal in 2% of
patients on anastrozole as compared with 1% in the
tamoxifen arm. The symptoms and changes correlate
with clinical, biochemical, and radiologic findings in
symptomatic women. To determine appropriate inter-
vention, it is therefore essential to perform a compre-
hensive evaluation of musculoskeletal complaints to
distinguish natural menopause-related degenerative
disease from AI-related effects. The present review
explores the advantages of differential diagnosis with
an emphasis on history and physical and musculo-
skeletal examination; laboratory investigations are used
to corroborate or rule out clinical impressions. The tran-
sient symptoms associated with the AIs are manage-
able with an appropriate combination of lifestyle
changes, including exercise and joint protection in con-
junction with pharmacologic approaches.
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1. INTRODUCTION
The benefit of aromatase inhibitors (AIs) in the treat-
ment of hormone-dependent early breast cancer is now
well established, leading to a recommendation for their
use as adjuvant therapy in postmenopausal women 1–4.
The underlying rationale for adjuvant treatment of
early-stage breast cancer following primary therapy
is to prevent or delay recurrence, although the goal is
also to increase the time to progression of the tumour
and to improve overall survival. Although disease-free
survival is approximately 5 times longer in cases of
early-stage disease than in cases of metastatic breast
cancer 5, patients at early stages of breast cancer who
receive adjuvant endocrine therapy still need to un-
derstand the safety and toxicity of the treatment.
2. MUSCULOSKELETAL COMPLAINTS
WITH AIs
Although the AIs are associated with fewer throm-
boembolic events and endometrial abnormalities than
is tamoxifen, approximately 25% of postmenopausal
women on AIs report arthralgia, skeletal, and muscle
pain 6.
The multicentre double-blind placebo-controlled
MA.17 trial by the National Cancer Institute of Canada
Clinical Trials Group compared 5 years of letrozole
therapy with 5 years of placebo in 5187 postmeno-
pausal women with breast cancer. The trial revealed
marked increases in arthralgia (25% vs. 21%) and
myalgia (15% vs. 12%) in patients on letrozole as
compared with those on placebo 7.
The Intergroup Exemestane Study, which en-
rolled 4742 postmenopausal women with hormone
receptor–positive or unknown breast cancer, has also
shown a link between arthralgia and the AI exemestane
(5.4% exemestane vs. 3.6% tamoxifen) 8. The
Arimidex, Tamoxifen Alone or in Combination (ATAC)
trial, which involved 9366 postmenopausal women
with localized breast cancer following surgery, was
one of the largest trials to investigate a third-genera-
tion AI as adjuvant therapy for breast cancer. In ATAC,
after 68 months’ median follow-up, the incidence of
arthralgia was significantly higher in the anastrozole
group than in the tamoxifen group [1100 of 3092
(35.6%) vs. 911 of 3094 (29.4%) patients] 9. In fact,
as compared with tamoxifen, anastrozole treatment
was associated with only a modest increase in the
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incidence of arthralgia. Nearly half (46%) of patients
with arthralgia syndrome reported exacerbation of a
pre-existing joint condition. Symptoms appeared
within the first 2 years of AI therapy (anastrozole 68%,
tamoxifen 59%), with a peak incidence at 6 months
(anastrozole 29%, tamoxifen 20%). However, half
of the patients who recovered were symptom-free
within 6 months of onset, and in 75% of patients,
symptoms resolved within 18 months. Most events
were mild to moderate in intensity, and only a small
fraction of patients (2% with anastrozole and 1% with
tamoxifen) discontinued treatment because of bone
symptoms 10.
2.1 Menopausal Arthritis and AI-Induced
Arthralgia
The prevalence of joint pain in the knees, hands, feet,
and other joints increases with age in women, reach-
ing a maximum in the group 50 to 59 years of age,
implicating hormonal changes 11,12. The prevalence
of osteoarthritis increases around menopause 13, and
rheumatoid arthritis has its highest incidence and
prevalence in the decade following menopause, per-
haps triggered by estrogen deprivation 14.
The physiologic underpinnings of joint pain in-
volve activation, by inflammatory mediators such as
prostaglandins and bradykinin, of the nociceptive fi-
bres innervating the articular structures. Activated
nociceptors increase sensitivity to pain caused by a
stimulus, including a mechanical stimulus. Inflamma-
tion leading to expansion of the nociceptor’s receptor
field enhances neural transmission and the overall pain
perception 15. The neuroprotective, anti-inflamma-
tory 16,17 and anti-nociceptive activities of estrogen are
believed to be mediated by estrogen receptors present
in the spinal cord and brain 18. Low estrogen levels
(resulting from aromatization of androgens) may there-
fore have a protective effect by directly affecting
opioid pain fibres in the central nervous system and
preventing inhibition of nociceptive neurons 19. Es-
trogen depletion during AI therapy of postmenopausal
early and advanced breast cancer results in enhanced
nociception and higher rates of arthralgia than are seen
with tamoxifen 8,20–22.
Unfortunately, coexisting conditions such as de-
generative joint disease, fibromyalgia, osteoporosis,
and degenerative disc disease contribute to worsen-
ing of the arthralgia or bone pain syndrome 23. Also,
arthralgia is a known side-effect of some medications,
including angiotensin converting-enzyme inhibitors,
proton pump inhibitors, quinolones, and tibolones.
Postmenopausal status is also an independent pre-
dictor of increased musculoskeletal pain, with estro-
gen deprivation contributing to arthralgia during
menopause and aromatase inhibition exacerbating
painful symptoms by further estrogen reduction 24.
The complex challenge facing the physician is
therefore to accurately distinguish arthralgia associ-
ated with AI therapy from bone disease and inflam-
matory and degenerative arthropathies, and from pain
secondary to other diseases. Tables I and II summa-
rize the various features of articular and nonarticular,
and inflammatory and non-inflammatory joint pain
respectively.
2.2 Clinical Evaluation of Musculoskeletal
Complaints
In the preliminary assessment of musculoskeletal
complaints, the emphasis is on patient history and
physical examination 26. Patients may describe stiff-
ness, aching, or pain in the hands, arms, knees, feet,
pelvic and hip bones, or back, which may be tempo-
rally associated with the start of AI therapy. This dis-
comfort is usually symmetrical, and may be associated
with mild soft-tissue thickening 27. The physician
should rule out conditions that require immediate at-
tention, including a history of significant trauma, a
hot and swollen joint, acute severe pain, fever, weight
loss, malaise, focal or diffuse muscle weakness, burn-
ing, numbness, paresthesia, and claudication 26,28
(Figure 1).
The next step entails determining whether the
condition is articular (pauci-articular, involving 3 or
fewer joints, or poly-articular, involving more than
3 joints) or non-articular; inflammatory or non-in-
flammatory; and acute (less than 6 weeks’ duration)
or chronic (6 weeks’ duration or longer). Complaints
of “joint pain” may originate from the joint itself or
from periarticular loci such as adjacent bone, liga-
ments, tendons, bursae, or soft tissues (Figure 1) 25,28.
2.2.1 Medical History
Appropriate medical history should include investi-
gation of the co-morbidities linked with musculo-
skeletal complaints: inflammatory bowel disease (IBD),
psoriasis, reactive arthritis, hemochromatosis, and
hypothyroidism. All medications should be reviewed
as completely as possible, including diuretics,
antihypertensives, anticonvulsants, cholesterol-lower-
ing agents, and others. Social history should be ex-
amined for work, sexuality, living, travel, and familial
patterns of connective tissue disease, psoriasis, IBD,
and gout. A systems review should also be undertaken
to note any other symptoms or infections of the gas-
trointestinal, genitourinary, ocular, and skin systems 25.
2.2.2 Physical and Musculoskeletal Examination
During the physical examination, the physician should
check for the presence of extra-articular features, in-
cluding nodules, tophi, or skin rashes (psoriasis), or
the presence of renal, pulmonary, neurologic, or ocu-
lar signs or symptoms. Any joint effusion may be clini-
cally significant and should be observed expectantly,
except when septic arthritis, osteomyelitis, fracture,
mechanical derangement, or tumour is suspected.
Lyme arthritis should be considered in patients withTHORNE
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new persistent inflammatory features—including ef-
fusions—in regions where Lyme disease is endemic,
or in patients with a history of travel to an endemic
area. Synovitis is usually indicated by the presence of
“stress pain” or an effusion.
Mal-alignment and bony enlargement may sug-
gest advanced osteoarthritis. On the other hand, joint
tenderness with full and painless passive range of
motion may indicate a peri-arthritis, including bursi-
tis, tendonitis, tenosynovitis, or enthesitis, but no in-
flammation of the synovial lining of the joint space
(Figure 1, Table I) 25.
2.2.3 Inflammation
The pattern and number of inflamed joints should
be observed: acute monoarthritis may represent sep-
tic arthritis or crystal arthritis (gout, for instance;
Table II). Oligoarthritis or polyarthritis involving the
hands and wrists but not the distal interphalangeal
joints is suggestive of rheumatoid arthritis. Early
symptoms of rheumatoid arthritis include morning
stiffness (more than 30 minutes) and three or more
swollen joints accompanied by metacarpophalangeal
or metatarsophalangeal involvement, which may be
simply demonstrated with the “squeeze test” 29.
TABLE I Articular compared with nonarticular disorders 25
Articular pain or tenderness Nonarticular pain
• Joint-specific
• Exacerbated with passive and active movement
• Specific referral patterns
• Frequent swelling: synovial effusion, thickening, and bony
enlargement
• Crepitation may be present
• Frequent mechanical symptoms—for example, locking,
instability
• Radiographic changes common in chronic and acute condi-
tions except trauma
• Originate from periarticular structures (tendons or bursae)
• Exacerbated with active range of motion
• Unusual symptoms and pain referral patterns
• Multiple somatic complaints
• Type of pain typical of fibromyalgia, hypochondriasis, and
pain amplification syndromes
• Uncommon
TABLE II Inflammatory compared with non-inflammatory joint pain 25
Inflammatory Non-inflammatory
Clinical features
Joint pain with activity and rest Joint pain improves with rest and worsens with activity
Morning stiffness >1 h Morning stiffness <1 h
Inflamed joints can lead to contractures Contractures unlikely
Crepitus may occur in inflammatory arthritis Crepitus usually absent
(felt as “soft”) (if present, “hard crepitus” bone on bone)
Radiologic changes seen —
Optional investigations
ESR, CRP elevated ESR, CRP normal
Synovial fluid cloudy Synovial fluid normal, straw coloured
Synovial fluid WBC > 2000/mL Synovial fluid WBC < 2000/mL
Synovial fluid neutrophils > 75% Synovial fluid neutrophils < 75%
Radiologic investigations: —
MRI, CT if tumour or infection is suspected
or if surgery is contemplated
Conditions
Rheumatoid arthritis Osteoarthritis
Psoriatic arthritis Trauma
Spondyloarthropathies Glucocorticoid withdrawal
Gout Hypertrophic osteoarthropathy
Pseudogout Avascular necrosis
Systemic lupus erythematosus Pigmented villonodular synovitis
Septic arthritis Hemochromatosis
Acromegaly
Charcot’s joint
ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; WBC = white blood cells; MRI = magnetic resonance imaging; CT = computed
tomography.MANAGEMENT OF ARTHRALGIAS WITH AI THERAPY
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FIGURE 1 Algorithm for assessment of musculoskeletal complaints (adapted 25,28,29).THORNE
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Psoriasis and osteoarthritis should be suspected
if the distal interphalangeal and proximal interpha-
langeal joints are involved. Gonococcal arthritis,
Rubella, and acute rheumatic fever may present with
a migratory polyarthritis. Spondyloarthropathy such
as ankylosing spondylitis, reactive arthritis (formerly
Reiter syndrome), psoriatic arthritis, or arthropathy
of IBD involve peripheral joints, enthuses, and whole
digits (dactylitis).
Myalgias and stiffness of the shoulder and pelvic
girdle that occur in patients more than 50 years of
age may be suggestive of polymyalgia rheumatica.MANAGEMENT OF ARTHRALGIAS WITH AI THERAPY
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Infection, metastatic malignancy, or neurologic causes
must be ruled out when evaluating new low back pain
in this group of patients.
2.2.4 Laboratory Investigation
The laboratory test that is most useful for evaluating
patients with inflammatory arthritis and an effusion
is synovial fluid analysis (Table II). The erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)
test are non-specific and may be elevated with other
conditions, including malignancy and infection.
Rheumatoid factor is also non-specific and increases
with age, regardless of the presence or absence of
joint disease. Patients with connective tissue diseases,
diffuse musculoskeletal symptoms, or drug-induced
diseases may have positive antinuclear antibodies.
2.3 Investigation of AI-Associated Arthralgia
The pathogenic and anatomic features of AI-induced
arthralgia have not been clearly delineated, but the
musculoskeletal symptoms and changes have been
investigated at the clinical, biochemical, and radio-
logic levels in symptomatic women. For instance,
after an average of 8 weeks’ treatment, the symp-
toms most commonly reported with AIs such as
letrozole or exemestane have been severe early morn-
ing stiffness and hand–wrist pain. Clinical signs in-
cluded severely limited mobility in the affected part
of the hand or wrist. “Trigger finger” and carpal tun-
nel syndrome were the most frequently reported clini-
cal signs, but inflammatory disease was ruled out in
the absence of elevation in CRP or ESR, although those
tests have not been assessed for sensitivity or speci-
ficity in this population. However, ultrasound ex-
amination showed fluid in the tendon sheath
surrounding the digital flexor tendons. Magnetic
resonance imaging (MRI) in various patients showed
fluid in the tendon sheaths of the digital flexor
muscles, intra-articular fluid accumulation in the
metacarpal joints, and synovitis of the radiocarpal
joint 6. Because of the prevalence of abnormal or
unexpected findings in asymptomatic patients, MRI
of the spine and computed tomography 30 should be
reserved for patients targeted for surgical interven-
tion or those in whom tumour or infection is a con-
cern. Laboratory and radiographic studies should be
used to corroborate clinical impressions or to rule
out causes that should not be missed. Systematic
clinical re-evaluation is imperative in the event of
uncertain diagnosis.
2.4 Management of Arthralgia
Studies reveal that the three most common sites of
arthralgia, in descending order, are knees, hands and
wrists, and shoulders, with the median severity scores
of AI-related joint symptoms being 7 for pain and 6
for stiffness on a scale of 0–10. However, more than
half of patients with AI-associated joint symptoms
reported relief with medications or supplements. Of
those taking an analgesic, 41% took acetaminophen,
59% took a nonsteroidal anti-inflammatory drug
(NSAID), and 12% took other medications. The me-
dian score for relief achieved with oral medications
was 7. In addition, 55% of patients used non-phar-
macologic interventions, mainly exercise, to allevi-
ate joint symptoms 31.
Compared with patients receiving tamoxifen, pa-
tients receiving anastrozole had only a modest increase
in joint symptoms, and most reported symptoms that
were mild to moderate in intensity, eliminating the
need for treatment withdrawal. Indeed, more than 90%
of patients treated for anastrozole-induced joint aches
and pains were managed with an NSAID alone or in
combination with mild analgesics 10.
The most appropriate intervention for pain man-
agement in AI-associated arthralgia may be a combi-
nation of lifestyle changes, such as introducing
weight-bearing exercise, abstaining from smoking,
being moderate in alcohol consumption, and taking
dietary calcium supplements and vitamin D for bone
protection in conjunction with pharmacologic ap-
proaches. Figure 2 contains a proposed algorithm for
the management of musculoskeletal symptoms in
patients taking an AI 32.
2.4.1 Non-pharmacologic Approaches to the
Management of Arthralgia
Chronic pain may be relieved either with heat, in the
form of warm showers or hot massage, or with acu-
puncture and acupressure techniques or transcutane-
ous electrical nerve stimulation 33. However, patients
with spinal osteoporosis should avoid deep muscle
massage 33. Preliminary results in more than a dozen
eligible patients investigated at the Columbia Uni-
versity College of Physicians and Surgeons 34 sug-
gested that acupuncture could be a potentially useful
intervention for improvements in index measures of
body pain and osteoarthritis.
Pain associated with arthralgia of the knees may
also be managed through patellar taping and appro-
priate footwear with lateral wedged insoles (Plourde
P. Arthralgia in postmenopausal breast cancer patients
on adjuvant endocrine therapy: a risk–benefit analy-
sis. Poster presentation at the Lynn Sage Breast Can-
cer Symposium; Chicago, IL; October 6–9, 2005).
Furthermore, regular stretching, joint mobility exer-
cises and physiotherapy to regain strength, increase
flexibility, relieve tension, and reduce fatigue are rec-
ommended. In addition, psychotherapy including re-
laxation training, biofeedback, visual imagery,
distraction methods, and psychiatric intervention
could effectively alleviate pain-related emotional
stress and depression 33, given the increased mood,
anxiety, and substance use disorders seen in patients
with musculoskeletal disorders, according to a large
Canadian community health survey 35.THORNE
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FIGURE 2 Management of musculoskeletal symptoms in patients with early breast cancer taking an aromatase inhibitor. † Misoprostol or
proton pump inhibitor. COX-2 = cyclooxygenase 2; IA = intra-articular; NSAID = nonsteroidal anti-inflammatory drug; OTC = over-the-counter;
TCA = tricyclic antidepressant.
2.4.2 Pharmacologic Approaches
Table III presents some pharmacologic options for
pain relief. Drug therapy for amelioration of pain
symptoms includes acetaminophen, NSAIDs such as
naproxen, mild opiates, strong opiates, and glu-
cosamine 23. Combination analgesics (for example,
acetaminophen with codeine or oxycodone) may be
used to provide additional short-term relief 28. In-
hibitors of COX2 may be a good choice when NSAIDs
are contraindicated. As well, topical medications
such as capsaicin and methylsalicylate may provide
pain relief. Antidepressants may help in the event
of comorbid depression associated with chronic
pain 36.
Bisphosphonates have been associated with mod-
est adjunctive analgesic benefits, but little clinical
evidence is available to support their use in early-
stage breast cancer 37,38. By helping to rebuild the
microarchitecture of bone, bisphosphonates may offer
women with early breast cancer some relief from ar-
thralgia 39. The correlation of AI-associated arthral-
gia with a low body mass index is still not clearly
established, although several possible mechanisms
associate the phenomenon with an incidence of
microfractures and local activation of inflammatory
mediators.
Patients with severe pain that is refractory to
simple analgesics or NSAIDs, and those who present
with new joint pain symptoms require a rheumatol-
ogic evaluation to rule out inflammatory conditions.
TABLE III Pharmacologic options for amelioration of pain in early
breast cancer patients with symptoms of arthralgia
Medication Dosage
Acetaminophen a £4 g daily (consider ER)
NSAID a Naproxen:
500–750 mg daily (analgesia)
1000–1500 mg daily (inflammation)
Cyclooxygenase Celecoxib: 100–200 mg daily b
inhibitors a
Tramadol £400 mg daily (consider ER)
Narcotics Codeine versus oxycodone
Pain modifiers TCA: nortriptyline 10–100 mg daily
Gabapentin, pregabalin
Intra-articular steroids Methylprednisolone acetate, triamcino-
lone suspension: 40 mg/cm3
a Minimum 2 weeks at tolerated dose.
b Maximum 400 mg daily.
NSAID = nonsteroidal anti-inflammatory drug; ER = extended release;
TCA = tricyclic antidepressant.MANAGEMENT OF ARTHRALGIAS WITH AI THERAPY
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3. CONCLUSION
Adverse events such as arthralgia and myalgia are
more frequent with adjuvant AI therapy than with
tamoxifen. However, they are predictable and may be
easily managed with appropriate lifestyle changes and
non-pharmacologic interventions, or with pain medi-
cations after accurate musculoskeletal evaluation and
differential diagnosis. Although a few studies suggest
the use of bisphosphonates to manage bone-related
side effects 40, current evidence is insufficient to sup-
port the use of those agents in preventing skeletal
events or improving survival in women with early-
stage breast cancer 37. Although the association of es-
trogen deprivation with osteoarthritis and rheumatoid
arthritis in postmenopausal women needs further
study, it is essential to understand that the symptoms
are usually transient and resolve when the AIs are dis-
continued at the end of therapy.
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